0
U.S. (TOLL FREE)
+1 (315) 215-3225
Automative

0
U.S. (TOLL FREE)
+1 (315) 215-3225
Global Meningococcal Group A and C Conjugate Vaccine Market Research Report 2026
Published Date: 2026-03-24
|
Report Code: QYRE-Auto-19A17700
Home | Market Reports | Health| Health Conditions| Infectious Diseases
Global Meningococcal Group A and C Conjugate Vaccine Market Research Report 2024
BUY CHAPTERS

Global Meningococcal Group A and C Conjugate Vaccine Market Research Report 2026

Code: QYRE-Auto-19A17700
Report
2026-03-24
Pages:97
QYResearch
Buy Now with 15% Discount
DESCRIPTION
TABLE OF CONTENT
TABLES & FIGURES

Meningococcal Group A and C Conjugate Vaccine Market

The global Meningococcal Group A and C Conjugate Vaccine market was valued at US$ million in 2025 and is anticipated to reach US$ million by 2032, at a CAGR of %from 2026 to 2032.
The 2025 U.S. tariff policies introduce profound uncertainty into the global economic landscape. This report critically examines the implications of recent tariff adjustments and international strategic countermeasures on Meningococcal Group A and C Conjugate Vaccine competitive dynamics, regional economic interdependencies, and supply chain reconfigurations.
The North American market for Meningococcal Group A and C Conjugate Vaccine is projected to increase from US$ million in 2025 to US$ million by 2032, at a CAGR of % over 2026–2032.
The Asia-Pacific market for Meningococcal Group A and C Conjugate Vaccine is projected to rise from US$ million in 2025 to US$ million by 2032, at a CAGR of % over 2026–2032.
Major global manufacturers of Meningococcal Group A and C Conjugate Vaccine include Sanofi Pasteur, GSK, Pfizer, Chongqing Zhifei Biological Products, etc. In 2025, the world's top three vendors accounted for approximately % of revenue.
This report delivers a comprehensive overview of the global Meningococcal Group A and C Conjugate Vaccine market, with both quantitative and qualitative analyses, to help readers develop growth strategies, assess the competitive landscape, evaluate their position in the current market, and make informed business decisions regarding Meningococcal Group A and C Conjugate Vaccine. The Meningococcal Group A and C Conjugate Vaccine market size, estimates, and forecasts are provided in terms of sales volume (K Units) and revenue (US$ millions), with 2025 as the base year and historical and forecast data for 2021–2032.
The report segments the global Meningococcal Group A and C Conjugate Vaccine market comprehensively. Regional market sizes by Type, by Application, , and by company are also provided. For deeper insight, the report profiles the competitive landscape, key competitors, and their respective market rankings, and discusses technological trends and new product developments.
This report will assist Meningococcal Group A and C Conjugate Vaccine manufacturers, new entrants, and companies across the industry value chain with information on revenues, sales volume, and average prices for the overall market and its sub-segments, by company, by Type, by Application, and by region.
Market Segmentation

Scope of Meningococcal Group A and C Conjugate Vaccine Market Report

Report Metric Details
Report Name Meningococcal Group A and C Conjugate Vaccine Market
Segment by Type
  • Prefilled
  • Non-prefilled
by Application
  • Adults
  • Children
Consumption by Region
  • North America (United States, Canada)
  • Europe (Germany, France, UK, Italy, Russia)
  • Asia-Pacific (China, Japan, South Korea, Taiwan)
  • Southeast Asia (India)
  • Latin America (Mexico, Brazil)
By Company Sanofi Pasteur, GSK, Pfizer, Chongqing Zhifei Biological Products
Forecast units USD million in value
Report coverage Revenue and volume forecast, company share, competitive landscape, growth factors and trends

Chapter Outline

  • Chapter 1: Defines the scope of the report and presents an executive summary of market segments (by Type, by Application, , etc.), including the size of each segment and its future growth potential. It offers a high-level view of the current market and its likely evolution in the short, medium, and long term.
  • Chapter 2: Provides a detailed analysis of the competitive landscape for Meningococcal Group A and C Conjugate Vaccine manufacturers, covering pricing, sales and revenue shares, latest development plans, and mergers and acquisitions.
  • Chapter 3: Examines Meningococcal Group A and C Conjugate Vaccine sales and revenue at the regional and country levels. It quantifies market size and growth potential for each region and its key countries, and outlines market development, outlook, addressable space, and national market size.
  • Chapter 4: Analyzes segments by Type, detailing the size and growth potential of each segment to help readers identify “blue ocean” opportunities.
  • Chapter 5: Analyzes market segments by Application, covering the size and growth potential of each segment to help readers identify “blue ocean” opportunities in downstream markets.
  • Chapter 6: Profiles key players, presenting core information on leading companies, including product sales, revenue, pricing, gross margin, product portfolio/introductions, and recent developments.
  • Chapter 7: Reviews the industry value chain, including upstream and downstream segments.
  • Chapter 8: Discusses market dynamics and recent developments, including drivers, restraints, challenges and risks for manufacturers, U.S. Tariffs and relevant policy analysis.
  • Chapter 9: Summarizes the key findings and conclusions of the report.

FAQ for this report

Who are the main players in the Meningococcal Group A and C Conjugate Vaccine Market report?

Ans: The main players in the Meningococcal Group A and C Conjugate Vaccine Market are Sanofi Pasteur, GSK, Pfizer, Chongqing Zhifei Biological Products

What are the Application segmentation covered in the Meningococcal Group A and C Conjugate Vaccine Market report?

Ans: The Applications covered in the Meningococcal Group A and C Conjugate Vaccine Market report are Adults, Children

What are the Type segmentation covered in the Meningococcal Group A and C Conjugate Vaccine Market report?

Ans: The Types covered in the Meningococcal Group A and C Conjugate Vaccine Market report are Prefilled, Non-prefilled

1 Meningococcal Group A and C Conjugate Vaccine Market Overview
1.1 Product Definition
1.2 Meningococcal Group A and C Conjugate Vaccine by Type
1.2.1 Global Meningococcal Group A and C Conjugate Vaccine Market Value by Type: 2025 vs 2032
1.2.2 Prefilled
1.2.3 Non-prefilled
1.3 Meningococcal Group A and C Conjugate Vaccine by Application
1.3.1 Global Meningococcal Group A and C Conjugate Vaccine Market Value by Application: 2025 vs 2032
1.3.2 Adults
1.3.3 Children
1.4 Global Meningococcal Group A and C Conjugate Vaccine Market Size Estimates and Forecasts
1.4.1 Global Meningococcal Group A and C Conjugate Vaccine Revenue 2021–2032
1.4.2 Global Meningococcal Group A and C Conjugate Vaccine Sales 2021–2032
1.4.3 Global Meningococcal Group A and C Conjugate Vaccine Market Average Price (2021–2032)
1.5 Assumptions and Limitations
2 Meningococcal Group A and C Conjugate Vaccine Market Competition by Manufacturers
2.1 Global Meningococcal Group A and C Conjugate Vaccine Sales Market Share by Manufacturers (2021–2026)
2.2 Global Meningococcal Group A and C Conjugate Vaccine Revenue Market Share by Manufacturers (2021–2026)
2.3 Global Meningococcal Group A and C Conjugate Vaccine Average Price by Manufacturers (2021–2026)
2.4 Global Key Players of Meningococcal Group A and C Conjugate Vaccine, Industry Ranking, 2023 vs 2024 vs 2025
2.5 Global Key Manufacturers of Meningococcal Group A and C Conjugate Vaccine, Manufacturing Sites and Headquarters
2.6 Global Key Manufacturers of Meningococcal Group A and C Conjugate Vaccine, Product Types and Applications
2.7 Global Key Manufacturers of Meningococcal Group A and C Conjugate Vaccine, Date of Entry into the Industry
2.8 Global Meningococcal Group A and C Conjugate Vaccine Market Competitive Situation and Trends
2.8.1 Global Meningococcal Group A and C Conjugate Vaccine Market Concentration Rate
2.8.2 The Top 5 and Top 10 Global Meningococcal Group A and C Conjugate Vaccine Players Market Share by Revenue
2.8.3 Global Meningococcal Group A and C Conjugate Vaccine Market Share by Company Tier (Tier 1, Tier 2, Tier 3)
2.9 Manufacturers Mergers & Acquisitions, Expansion Plans
3 Global Meningococcal Group A and C Conjugate Vaccine Market Scenario by Region
3.1 Global Meningococcal Group A and C Conjugate Vaccine Market Size by Region: 2021 vs 2025 vs 2032
3.2 Global Meningococcal Group A and C Conjugate Vaccine Sales by Region: 2021–2032
3.2.1 Global Meningococcal Group A and C Conjugate Vaccine Sales by Region: 2021–2026
3.2.2 Global Meningococcal Group A and C Conjugate Vaccine Sales by Region: 2027–2032
3.3 Global Meningococcal Group A and C Conjugate Vaccine Revenue by Region: 2021–2032
3.3.1 Global Meningococcal Group A and C Conjugate Vaccine Revenue by Region: 2021–2026
3.3.2 Global Meningococcal Group A and C Conjugate Vaccine Revenue by Region: 2027–2032
3.4 North America Meningococcal Group A and C Conjugate Vaccine Market Facts & Figures by Country
3.4.1 North America Meningococcal Group A and C Conjugate Vaccine Market Size by Country: 2021 vs 2025 vs 2032
3.4.2 North America Meningococcal Group A and C Conjugate Vaccine Sales by Country (2021–2032)
3.4.3 North America Meningococcal Group A and C Conjugate Vaccine Revenue by Country (2021–2032)
3.4.4 United States
3.4.5 Canada
3.5 Europe Meningococcal Group A and C Conjugate Vaccine Market Facts & Figures by Country
3.5.1 Europe Meningococcal Group A and C Conjugate Vaccine Market Size by Country: 2021 vs 2025 vs 2032
3.5.2 Europe Meningococcal Group A and C Conjugate Vaccine Sales by Country (2021–2032)
3.5.3 Europe Meningococcal Group A and C Conjugate Vaccine Revenue by Country (2021–2032)
3.5.4 Germany
3.5.5 France
3.5.6 U.K.
3.5.7 Italy
3.5.8 Russia
3.6 Asia Pacific Meningococcal Group A and C Conjugate Vaccine Market Facts & Figures by Region
3.6.1 Asia Pacific Meningococcal Group A and C Conjugate Vaccine Market Size by Region: 2021 vs 2025 vs 2032
3.6.2 Asia Pacific Meningococcal Group A and C Conjugate Vaccine Sales by Region (2021–2032)
3.6.3 Asia Pacific Meningococcal Group A and C Conjugate Vaccine Revenue by Region (2021–2032)
3.6.4 China
3.6.5 Japan
3.6.6 South Korea
3.6.7 India
3.6.8 Australia
3.6.9 China Taiwan
3.6.10 Southeast Asia
3.7 Latin America Meningococcal Group A and C Conjugate Vaccine Market Facts & Figures by Country
3.7.1 Latin America Meningococcal Group A and C Conjugate Vaccine Market Size by Country: 2021 vs 2025 vs 2032
3.7.2 Latin America Meningococcal Group A and C Conjugate Vaccine Sales by Country (2021–2032)
3.7.3 Latin America Meningococcal Group A and C Conjugate Vaccine Revenue by Country (2021–2032)
3.7.4 Mexico
3.7.5 Brazil
3.7.6 Argentina
3.7.7 Colombia
3.8 Middle East and Africa Meningococcal Group A and C Conjugate Vaccine Market Facts & Figures by Country
3.8.1 Middle East and Africa Meningococcal Group A and C Conjugate Vaccine Market Size by Country: 2021 vs 2025 vs 2032
3.8.2 Middle East and Africa Meningococcal Group A and C Conjugate Vaccine Sales by Country (2021–2032)
3.8.3 Middle East and Africa Meningococcal Group A and C Conjugate Vaccine Revenue by Country (2021–2032)
3.8.4 Turkey
3.8.5 Saudi Arabia
3.8.6 UAE
4 Segment by Type
4.1 Global Meningococcal Group A and C Conjugate Vaccine Sales by Type (2021–2032)
4.1.1 Global Meningococcal Group A and C Conjugate Vaccine Sales by Type (2021–2026)
4.1.2 Global Meningococcal Group A and C Conjugate Vaccine Sales by Type (2027–2032)
4.1.3 Global Meningococcal Group A and C Conjugate Vaccine Sales Market Share by Type (2021–2032)
4.2 Global Meningococcal Group A and C Conjugate Vaccine Revenue by Type (2021–2032)
4.2.1 Global Meningococcal Group A and C Conjugate Vaccine Revenue by Type (2021–2026)
4.2.2 Global Meningococcal Group A and C Conjugate Vaccine Revenue by Type (2027–2032)
4.2.3 Global Meningococcal Group A and C Conjugate Vaccine Revenue Market Share by Type (2021–2032)
4.3 Global Meningococcal Group A and C Conjugate Vaccine Price by Type (2021–2032)
5 Segment by Application
5.1 Global Meningococcal Group A and C Conjugate Vaccine Sales by Application (2021–2032)
5.1.1 Global Meningococcal Group A and C Conjugate Vaccine Sales by Application (2021–2026)
5.1.2 Global Meningococcal Group A and C Conjugate Vaccine Sales by Application (2027–2032)
5.1.3 Global Meningococcal Group A and C Conjugate Vaccine Sales Market Share by Application (2021–2032)
5.2 Global Meningococcal Group A and C Conjugate Vaccine Revenue by Application (2021–2032)
5.2.1 Global Meningococcal Group A and C Conjugate Vaccine Revenue by Application (2021–2026)
5.2.2 Global Meningococcal Group A and C Conjugate Vaccine Revenue by Application (2027–2032)
5.2.3 Global Meningococcal Group A and C Conjugate Vaccine Revenue Market Share by Application (2021–2032)
5.3 Global Meningococcal Group A and C Conjugate Vaccine Price by Application (2021–2032)
6 Key Companies Profiled
6.1 Sanofi Pasteur
6.1.1 Sanofi Pasteur Company Information
6.1.2 Sanofi Pasteur Description and Business Overview
6.1.3 Sanofi Pasteur Meningococcal Group A and C Conjugate Vaccine Sales, Revenue, and Gross Margin (2021–2026)
6.1.4 Sanofi Pasteur Meningococcal Group A and C Conjugate Vaccine Product Portfolio
6.1.5 Sanofi Pasteur Recent Developments/Updates
6.2 GSK
6.2.1 GSK Company Information
6.2.2 GSK Description and Business Overview
6.2.3 GSK Meningococcal Group A and C Conjugate Vaccine Sales, Revenue, and Gross Margin (2021–2026)
6.2.4 GSK Meningococcal Group A and C Conjugate Vaccine Product Portfolio
6.2.5 GSK Recent Developments/Updates
6.3 Pfizer
6.3.1 Pfizer Company Information
6.3.2 Pfizer Description and Business Overview
6.3.3 Pfizer Meningococcal Group A and C Conjugate Vaccine Sales, Revenue, and Gross Margin (2021–2026)
6.3.4 Pfizer Meningococcal Group A and C Conjugate Vaccine Product Portfolio
6.3.5 Pfizer Recent Developments/Updates
6.4 Chongqing Zhifei Biological Products
6.4.1 Chongqing Zhifei Biological Products Company Information
6.4.2 Chongqing Zhifei Biological Products Description and Business Overview
6.4.3 Chongqing Zhifei Biological Products Meningococcal Group A and C Conjugate Vaccine Sales, Revenue, and Gross Margin (2021–2026)
6.4.4 Chongqing Zhifei Biological Products Meningococcal Group A and C Conjugate Vaccine Product Portfolio
6.4.5 Chongqing Zhifei Biological Products Recent Developments/Updates
7 Industry Chain and Sales Channels Analysis
7.1 Meningococcal Group A and C Conjugate Vaccine Industry Chain Analysis
7.2 Meningococcal Group A and C Conjugate Vaccine Raw Material Supply Analysis
7.2.1 Key Raw Materials
7.2.2 Raw Materials Key Suppliers
7.3 Meningococcal Group A and C Conjugate Vaccine Production Mode & Process Analysis
7.4 Meningococcal Group A and C Conjugate Vaccine Sales and Marketing
7.4.1 Meningococcal Group A and C Conjugate Vaccine Sales Channels
7.4.2 Meningococcal Group A and C Conjugate Vaccine Distributors
7.5 Meningococcal Group A and C Conjugate Vaccine Customer Analysis
8 Meningococcal Group A and C Conjugate Vaccine Market Dynamics
8.1 Meningococcal Group A and C Conjugate Vaccine Industry Trends
8.2 Meningococcal Group A and C Conjugate Vaccine Market Drivers
8.3 Meningococcal Group A and C Conjugate Vaccine Market Challenges
8.4 Meningococcal Group A and C Conjugate Vaccine Market Restraints
8.5 Impact of U.S. Tariffs
9 Research Findings and Conclusion
10 Methodology and Data Source
10.1 Methodology/Research Approach
10.1.1 Research Programs/Design
10.1.2 Market Size Estimation
10.1.3 Market Breakdown and Data Triangulation
10.2 Data Source
10.2.1 Secondary Sources
10.2.2 Primary Sources
10.3 Author List
10.4 Disclaimer
List of Tables
 Table 1. Global Meningococcal Group A and C Conjugate Vaccine Market Value by Type (US$ Million), 2025 vs 2032
 Table 2. Global Meningococcal Group A and C Conjugate Vaccine Market Value by Application (US$ Million), 2025 vs 2032
 Table 3. Global Meningococcal Group A and C Conjugate Vaccine Market Competitive Situation by Manufacturers in 2025
 Table 4. Global Meningococcal Group A and C Conjugate Vaccine Sales (K Units) of Key Manufacturers (2021–2026)
 Table 5. Global Meningococcal Group A and C Conjugate Vaccine Sales Market Share by Manufacturers (2021–2026)
 Table 6. Global Meningococcal Group A and C Conjugate Vaccine Revenue (US$ Million) by Manufacturers (2021–2026)
 Table 7. Global Meningococcal Group A and C Conjugate Vaccine Revenue Share by Manufacturers (2021–2026)
 Table 8. Global Market Meningococcal Group A and C Conjugate Vaccine Average Price (US$/Unit) of Key Manufacturers (2021–2026)
 Table 9. Global Key Players of Meningococcal Group A and C Conjugate Vaccine, Industry Ranking, 2023 vs 2024 vs 2025
 Table 10. Global Key Manufacturers of Meningococcal Group A and C Conjugate Vaccine, Manufacturing Sites and Headquarters
 Table 11. Global Key Manufacturers of Meningococcal Group A and C Conjugate Vaccine, Product Types and Applications
 Table 12. Global Key Manufacturers of Meningococcal Group A and C Conjugate Vaccine, Date of Entry into the Industry
 Table 13. Global Manufacturers Market Concentration Ratio (CR5 and HHI)
 Table 14. Global Meningococcal Group A and C Conjugate Vaccine Companies by Tier (Tier 1, Tier 2, Tier 3), based on Meningococcal Group A and C Conjugate Vaccine Revenue, 2025
 Table 15. Manufacturers Mergers & Acquisitions, Expansion Plans
 Table 16. Global Meningococcal Group A and C Conjugate Vaccine Market Size by Region (US$ Million): 2021 vs 2025 vs 2032
 Table 17. Global Meningococcal Group A and C Conjugate Vaccine Sales by Region (K Units), 2021–2026
 Table 18. Global Meningococcal Group A and C Conjugate Vaccine Sales Market Share by Region (2021–2026)
 Table 19. Global Meningococcal Group A and C Conjugate Vaccine Sales by Region (K Units), 2027–2032
 Table 20. Global Meningococcal Group A and C Conjugate Vaccine Sales Market Share by Region (2027–2032)
 Table 21. Global Meningococcal Group A and C Conjugate Vaccine Revenue by Region (US$ Million), 2021–2026
 Table 22. Global Meningococcal Group A and C Conjugate Vaccine Revenue Market Share by Region (2021–2026)
 Table 23. Global Meningococcal Group A and C Conjugate Vaccine Revenue by Region (US$ Million), 2027–2032
 Table 24. Global Meningococcal Group A and C Conjugate Vaccine Revenue Market Share by Region (2027–2032)
 Table 25. North America Meningococcal Group A and C Conjugate Vaccine Revenue by Country: 2021 vs 2025 vs 2032 (US$ Million)
 Table 26. North America Meningococcal Group A and C Conjugate Vaccine Sales by Country (K Units), 2021–2026
 Table 27. North America Meningococcal Group A and C Conjugate Vaccine Sales by Country (K Units), 2027–2032
 Table 28. North America Meningococcal Group A and C Conjugate Vaccine Revenue by Country (US$ Million), 2021–2026
 Table 29. North America Meningococcal Group A and C Conjugate Vaccine Revenue by Country (US$ Million), 2027–2032
 Table 30. Europe Meningococcal Group A and C Conjugate Vaccine Revenue by Country: 2021 vs 2025 vs 2032 (US$ Million)
 Table 31. Europe Meningococcal Group A and C Conjugate Vaccine Sales by Country (K Units), 2021–2026
 Table 32. Europe Meningococcal Group A and C Conjugate Vaccine Sales by Country (K Units), 2027–2032
 Table 33. Europe Meningococcal Group A and C Conjugate Vaccine Revenue by Country (US$ Million), 2021–2026
 Table 34. Europe Meningococcal Group A and C Conjugate Vaccine Revenue by Country (US$ Million), 2027–2032
 Table 35. Asia Pacific Meningococcal Group A and C Conjugate Vaccine Revenue by Region: 2021 vs 2025 vs 2032 (US$ Million)
 Table 36. Asia Pacific Meningococcal Group A and C Conjugate Vaccine Sales by Region (K Units), 2021–2026
 Table 37. Asia Pacific Meningococcal Group A and C Conjugate Vaccine Sales by Region (K Units), 2027–2032
 Table 38. Asia Pacific Meningococcal Group A and C Conjugate Vaccine Revenue by Region (US$ Million), 2021–2026
 Table 39. Asia Pacific Meningococcal Group A and C Conjugate Vaccine Revenue by Region (US$ Million), 2027–2032
 Table 40. Latin America Meningococcal Group A and C Conjugate Vaccine Revenue by Country: 2021 vs 2025 vs 2032 (US$ Million)
 Table 41. Latin America Meningococcal Group A and C Conjugate Vaccine Sales by Country (K Units), 2021–2026
 Table 42. Latin America Meningococcal Group A and C Conjugate Vaccine Sales by Country (K Units), 2027–2032
 Table 43. Latin America Meningococcal Group A and C Conjugate Vaccine Revenue by Country (US$ Million), 2021–2026
 Table 44. Latin America Meningococcal Group A and C Conjugate Vaccine Revenue by Country (US$ Million), 2027–2032
 Table 45. Middle East and Africa Meningococcal Group A and C Conjugate Vaccine Revenue by Country: 2021 vs 2025 vs 2032 (US$ Million)
 Table 46. Middle East and Africa Meningococcal Group A and C Conjugate Vaccine Sales by Country (K Units), 2021–2026
 Table 47. Middle East and Africa Meningococcal Group A and C Conjugate Vaccine Sales by Country (K Units), 2027–2032
 Table 48. Middle East and Africa Meningococcal Group A and C Conjugate Vaccine Revenue by Country (US$ Million), 2021–2026
 Table 49. Middle East and Africa Meningococcal Group A and C Conjugate Vaccine Revenue by Country (US$ Million), 2027–2032
 Table 50. Global Meningococcal Group A and C Conjugate Vaccine Sales (K Units) by Type (2021–2026)
 Table 51. Global Meningococcal Group A and C Conjugate Vaccine Sales (K Units) by Type (2027–2032)
 Table 52. Global Meningococcal Group A and C Conjugate Vaccine Sales Market Share by Type (2021–2026)
 Table 53. Global Meningococcal Group A and C Conjugate Vaccine Sales Market Share by Type (2027–2032)
 Table 54. Global Meningococcal Group A and C Conjugate Vaccine Revenue (US$ Million) by Type (2021–2026)
 Table 55. Global Meningococcal Group A and C Conjugate Vaccine Revenue (US$ Million) by Type (2027–2032)
 Table 56. Global Meningococcal Group A and C Conjugate Vaccine Revenue Market Share by Type (2021–2026)
 Table 57. Global Meningococcal Group A and C Conjugate Vaccine Revenue Market Share by Type (2027–2032)
 Table 58. Global Meningococcal Group A and C Conjugate Vaccine Price (US$/Unit) by Type (2021–2026)
 Table 59. Global Meningococcal Group A and C Conjugate Vaccine Price (US$/Unit) by Type (2027–2032)
 Table 60. Global Meningococcal Group A and C Conjugate Vaccine Sales (K Units) by Application (2021–2026)
 Table 61. Global Meningococcal Group A and C Conjugate Vaccine Sales (K Units) by Application (2027–2032)
 Table 62. Global Meningococcal Group A and C Conjugate Vaccine Sales Market Share by Application (2021–2026)
 Table 63. Global Meningococcal Group A and C Conjugate Vaccine Sales Market Share by Application (2027–2032)
 Table 64. Global Meningococcal Group A and C Conjugate Vaccine Revenue (US$ Million) by Application (2021–2026)
 Table 65. Global Meningococcal Group A and C Conjugate Vaccine Revenue (US$ Million) by Application (2027–2032)
 Table 66. Global Meningococcal Group A and C Conjugate Vaccine Revenue Market Share by Application (2021–2026)
 Table 67. Global Meningococcal Group A and C Conjugate Vaccine Revenue Market Share by Application (2027–2032)
 Table 68. Global Meningococcal Group A and C Conjugate Vaccine Price (US$/Unit) by Application (2021–2026)
 Table 69. Global Meningococcal Group A and C Conjugate Vaccine Price (US$/Unit) by Application (2027–2032)
 Table 70. Sanofi Pasteur Company Information
 Table 71. Sanofi Pasteur Description and Business Overview
 Table 72. Sanofi Pasteur Meningococcal Group A and C Conjugate Vaccine Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
 Table 73. Sanofi Pasteur Meningococcal Group A and C Conjugate Vaccine Product
 Table 74. Sanofi Pasteur Recent Developments/Updates
 Table 75. GSK Company Information
 Table 76. GSK Description and Business Overview
 Table 77. GSK Meningococcal Group A and C Conjugate Vaccine Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
 Table 78. GSK Meningococcal Group A and C Conjugate Vaccine Product
 Table 79. GSK Recent Developments/Updates
 Table 80. Pfizer Company Information
 Table 81. Pfizer Description and Business Overview
 Table 82. Pfizer Meningococcal Group A and C Conjugate Vaccine Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
 Table 83. Pfizer Meningococcal Group A and C Conjugate Vaccine Product
 Table 84. Pfizer Recent Developments/Updates
 Table 85. Chongqing Zhifei Biological Products Company Information
 Table 86. Chongqing Zhifei Biological Products Description and Business Overview
 Table 87. Chongqing Zhifei Biological Products Meningococcal Group A and C Conjugate Vaccine Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
 Table 88. Chongqing Zhifei Biological Products Meningococcal Group A and C Conjugate Vaccine Product
 Table 89. Chongqing Zhifei Biological Products Recent Developments/Updates
 Table 90. Key Raw Materials Lists
 Table 91. Raw Materials Key Suppliers Lists
 Table 92. Meningococcal Group A and C Conjugate Vaccine Distributors List
 Table 93. Meningococcal Group A and C Conjugate Vaccine Customers List
 Table 94. Meningococcal Group A and C Conjugate Vaccine Market Trends
 Table 95. Meningococcal Group A and C Conjugate Vaccine Market Drivers
 Table 96. Meningococcal Group A and C Conjugate Vaccine Market Challenges
 Table 97. Meningococcal Group A and C Conjugate Vaccine Market Restraints
 Table 98. Research Programs/Design for This Report
 Table 99. Key Data Information from Secondary Sources
 Table 100. Key Data Information from Primary Sources
 Table 101. Authors List of This Report


List of Figures
 Figure 1. Product Picture of Meningococcal Group A and C Conjugate Vaccine
 Figure 2. Global Meningococcal Group A and C Conjugate Vaccine Market Value by Type (US$ Million), 2021–2032
 Figure 3. Global Meningococcal Group A and C Conjugate Vaccine Market Share by Type: 2025 & 2032
 Figure 4. Prefilled Product Picture
 Figure 5. Non-prefilled Product Picture
 Figure 6. Global Meningococcal Group A and C Conjugate Vaccine Market Value by Application (US$ Million), 2021–2032
 Figure 7. Global Meningococcal Group A and C Conjugate Vaccine Market Share by Application: 2025 & 2032
 Figure 8. Adults
 Figure 9. Children
 Figure 10. Global Meningococcal Group A and C Conjugate Vaccine Revenue, (US$ Million), 2021 vs 2025 vs 2032
 Figure 11. Global Meningococcal Group A and C Conjugate Vaccine Market Size (US$ Million), 2021–2032
 Figure 12. Global Meningococcal Group A and C Conjugate Vaccine Sales (K Units), 2021–2032
 Figure 13. Global Meningococcal Group A and C Conjugate Vaccine Average Price (US$/Unit), 2021–2032
 Figure 14. Meningococcal Group A and C Conjugate Vaccine Report Years Considered
 Figure 15. Meningococcal Group A and C Conjugate Vaccine Sales Share by Manufacturers in 2025
 Figure 16. Global Meningococcal Group A and C Conjugate Vaccine Revenue Share by Manufacturers in 2025
 Figure 17. Top 5 and Top 10 Global Meningococcal Group A and C Conjugate Vaccine Players: Market Share by Revenue in Meningococcal Group A and C Conjugate Vaccine in 2025
 Figure 18. Meningococcal Group A and C Conjugate Vaccine Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2021 vs 2025
 Figure 19. Global Meningococcal Group A and C Conjugate Vaccine Market Size by Region (US$ Million): 2021 vs 2025 vs 2032
 Figure 20. North America Meningococcal Group A and C Conjugate Vaccine Sales Market Share by Country (2021–2032)
 Figure 21. North America Meningococcal Group A and C Conjugate Vaccine Revenue Market Share by Country (2021–2032)
 Figure 22. United States Meningococcal Group A and C Conjugate Vaccine Revenue Growth Rate (US$ Million), 2021–2032
 Figure 23. Canada Meningococcal Group A and C Conjugate Vaccine Revenue Growth Rate (US$ Million), 2021–2032
 Figure 24. Europe Meningococcal Group A and C Conjugate Vaccine Sales Market Share by Country (2021–2032)
 Figure 25. Europe Meningococcal Group A and C Conjugate Vaccine Revenue Market Share by Country (2021–2032)
 Figure 26. Germany Meningococcal Group A and C Conjugate Vaccine Revenue Growth Rate (US$ Million), 2021–2032
 Figure 27. France Meningococcal Group A and C Conjugate Vaccine Revenue Growth Rate (US$ Million), 2021–2032
 Figure 28. U.K. Meningococcal Group A and C Conjugate Vaccine Revenue Growth Rate (US$ Million), 2021–2032
 Figure 29. Italy Meningococcal Group A and C Conjugate Vaccine Revenue Growth Rate (US$ Million), 2021–2032
 Figure 30. Russia Meningococcal Group A and C Conjugate Vaccine Revenue Growth Rate (US$ Million), 2021–2032
 Figure 31. Asia Pacific Meningococcal Group A and C Conjugate Vaccine Sales Market Share by Region (2021–2032)
 Figure 32. Asia Pacific Meningococcal Group A and C Conjugate Vaccine Revenue Market Share by Region (2021–2032)
 Figure 33. China Meningococcal Group A and C Conjugate Vaccine Revenue Growth Rate (US$ Million), 2021–2032
 Figure 34. Japan Meningococcal Group A and C Conjugate Vaccine Revenue Growth Rate (US$ Million), 2021–2032
 Figure 35. South Korea Meningococcal Group A and C Conjugate Vaccine Revenue Growth Rate (US$ Million), 2021–2032
 Figure 36. India Meningococcal Group A and C Conjugate Vaccine Revenue Growth Rate (US$ Million), 2021–2032
 Figure 37. Australia Meningococcal Group A and C Conjugate Vaccine Revenue Growth Rate (US$ Million), 2021–2032
 Figure 38. China Taiwan Meningococcal Group A and C Conjugate Vaccine Revenue Growth Rate (US$ Million), 2021–2032
 Figure 39. Southeast Asia Meningococcal Group A and C Conjugate Vaccine Revenue Growth Rate (US$ Million), 2021–2032
 Figure 40. Latin America Meningococcal Group A and C Conjugate Vaccine Sales Market Share by Country (2021–2032)
 Figure 41. Latin America Meningococcal Group A and C Conjugate Vaccine Revenue Market Share by Country (2021–2032)
 Figure 42. Mexico Meningococcal Group A and C Conjugate Vaccine Revenue Growth Rate (US$ Million), 2021–2032
 Figure 43. Brazil Meningococcal Group A and C Conjugate Vaccine Revenue Growth Rate (US$ Million), 2021–2032
 Figure 44. Argentina Meningococcal Group A and C Conjugate Vaccine Revenue Growth Rate (US$ Million), 2021–2032
 Figure 45. Colombia Meningococcal Group A and C Conjugate Vaccine Revenue Growth Rate (US$ Million), 2021–2032
 Figure 46. Middle East and Africa Meningococcal Group A and C Conjugate Vaccine Sales Market Share by Country (2021–2032)
 Figure 47. Middle East and Africa Meningococcal Group A and C Conjugate Vaccine Revenue Market Share by Country (2021–2032)
 Figure 48. Turkey Meningococcal Group A and C Conjugate Vaccine Revenue Growth Rate (US$ Million), 2021–2032
 Figure 49. Saudi Arabia Meningococcal Group A and C Conjugate Vaccine Revenue Growth Rate (US$ Million), 2021–2032
 Figure 50. UAE Meningococcal Group A and C Conjugate Vaccine Revenue Growth Rate (US$ Million), 2021–2032
 Figure 51. Global Sales Market Share of Meningococcal Group A and C Conjugate Vaccine by Type (2021–2032)
 Figure 52. Global Revenue Market Share of Meningococcal Group A and C Conjugate Vaccine by Type (2021–2032)
 Figure 53. Global Meningococcal Group A and C Conjugate Vaccine Price (US$/Unit) by Type (2021–2032)
 Figure 54. Global Sales Market Share of Meningococcal Group A and C Conjugate Vaccine by Application (2021–2032)
 Figure 55. Global Revenue Market Share of Meningococcal Group A and C Conjugate Vaccine by Application (2021–2032)
 Figure 56. Global Meningococcal Group A and C Conjugate Vaccine Price (US$/Unit) by Application (2021–2032)
 Figure 57. Meningococcal Group A and C Conjugate Vaccine Value Chain
 Figure 58. Channels of Distribution (Direct Vs Distribution)
 Figure 59. Bottom-up and Top-down Approaches for This Report
 Figure 60. Data Triangulation
 Figure 61. Key Executives Interviewed
SELECT A FORMAT
Added to Cart
Electronic

$2900

Single User License
Electronic

$4350

Multi User License
Electronic

$5800

Enterprise License
Add to Cart
Buy Now (15% Discount)

OUR CUSTOMER

Leap India

SIMILAR REPORTS